Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc
 
 
Facebook
 
ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

ME/CFS: From Pathophysiological Insights To Novel Therapeutic Opportunities

Friday 25 October 2019

 

From Pharmacological Research:

 

Doctor and patient
 

Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.

Morris G1, Puri BK2, Walker AJ1, Maes M1, Carvalho AF3, Walder K4, Mazza C1, Berk M5.

  1. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Barwon Health, Geelong, Australia.
  2. Department of Medicine, Hammersmith Hospital, Imperial College London, London, UK.
  3. Department of Psychiatry, University of Toronto, Toronto, ON, Canada; The Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
  4. CMMR Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia.
  5. IMPACT Strategic Research Centre, School of Medicine, Deakin University, Barwon Health, Geelong, Australia; CMMR Strategic Research Centre, School of Medicine, Deakin University, Geelong, Victoria, Australia; Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia.; The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Australia; Department of Psychiatry, University of Melbourne, Parkville, Australia.. Electronic address: michael.berk@barwonhealth.org.au.

 2019 Sep 8:104450. doi: 10.1016/j.phrs.2019.104450. [Epub ahead of print]

Copyright © 2019 Elsevier Ltd. All rights reserved.

Abstract

Myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) is a common and disabling condition with a paucity of effective and evidence-based therapies, reflecting a major unmet need.

Cognitive behavioural therapy and graded exercise are of modest benefit for only some ME/CFS patients, and many sufferers report aggravation of symptoms of fatigue with exercise.

The presence of a multiplicity of pathophysiological abnormalities in at least the subgroup of people with ME/CFS diagnosed with the current international consensus "Fukuda" criteria, points to numerous potential therapeutic targets.

Such abnormalities include extensive data showing that at least a subgroup has a pro-inflammatory state, increased oxidative and nitrosative stress, disruption of gut mucosal barriers and mitochondrial dysfunction together with dysregulated bioenergetics.

In this paper, these pathways are summarised, and data regarding promising therapeutic options that target these pathways are highlighted; they include coenzyme Q10, melatonin, curcumin, molecular hydrogen and N-acetylcysteine.

These data are promising yet preliminary, suggesting hopeful avenues to address this major unmet burden of illness.

 

Full article…

 


 

blog comments powered by Disqus
Previous Previous Page